Dendrite Appoints Jeff Bairstow as Executive Vice President and Chief Financial Officer

Mr. Bairstow joins Dendrite from RelayHealth Corporation, thenation's premier provider of health plan-reimbursed onlinedoctor-patient communication services, where he has served as ChiefOperating Officer since 2004.

Mr. Bairstow previously held senior financial and operationalresponsibilities within Health Net Inc. (NYSE: HNT), including asPresident of Health Net's Government and Specialty Services Divisionand earlier as Executive Vice President and Chief Financial Officer ofHealth Net-California. Mr. Bairstow also held a number of executivepositions at other public and private companies within the healthcareindustry, including America Service Group (NASDAQ: ASGR) and ManagedHealth Network, after beginning his career at Ernst & Whinney.

"When Dendrite approached me I became enthused by the remit tohelp them take a leading role in providing the solutions thatintegrate the promotional activities and improve the productivity ofthe global pharmaceutical industry. I am very pleased to join the teamcharged with growing the company into this enormous opportunity."

"Jeff is a broadly skilled executive who brings strong leadershipand financial experience to Dendrite. He will lead the maturation ofour financial and other management processes to help ensure we areappropriately structured for the growth we see ahead. Additionally, asa senior, experienced healthcare executive, he will be invaluable ashe joins Joe Ripp in driving Dendrite's innovation as we reach forhigher levels of performance," said John Bailye, Dendrite's Chairmanand Chief Executive Officer.

Mr. Bairstow graduated from Vanderbilt University in 1980 with aBachelor of Arts degree and earned his Master's of BusinessAdministration in 1982 from Vanderbilt's Owen School of Business.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) providesdiversified sales, marketing, clinical and compliance solutions to theglobal life sciences and pharmaceutical industry. With clients in morethan 50 countries, including the world's top 20 pharmaceuticalcompanies, Dendrite strives to be the first source for expertpromotional and sales effectiveness solutions. For more information,please visit www.dendrite.com.

Note: Dendrite is a registered trademark of DendriteInternational, Inc.

This document may contain forward-looking statements that may beidentified by such forward-looking terminology as "expect," "believe,""anticipate," "will," "intend," "plan," "target," "outlook,""guidance," and similar statements or variations. Such forward-lookingstatements are based on our current expectations, estimates,assumptions and projections and involve significant risks anduncertainties, including risks which may result from our dependence onthe pharmaceutical industry; fluctuations in quarterly revenues due tolengthy sales and implementation cycles for certain of our solutions;our fixed expenses in relation to fluctuating revenues and variationsin customers' budget cycles; dependence on certain major customers;changes in demand for our products and services attributable to anyweakness experienced in the economy or mergers, acquisitions andconsolidations in the pharmaceutical industry; successful and timelydevelopment and introduction of new products and versions; rapidtechnological changes; increased competition; internationaloperations; integrating the entities we acquire; our ability toeffectively manage our growth; the protection of our proprietarytechnology; our ability to compete in the Internet-related productsand services market; the continued demand for Internet-relatedproducts and services; the ability of our third party vendors torespond to technological change; our ability to maintain ourrelationships with third-party vendors; less favorable thananticipated results from strategic relationships; dependence of datasolutions on strategic relationships; events which may affect the U.S.and world economies; and catastrophic events which could negativelyaffect our information technology infrastructure. Other importantfactors that should be reviewed and carefully considered are includedin the company's 10-K, 10-Qs, and other reports filed with the SEC.Actual results may differ materially. The company assumes noobligation for updating any such forward-looking statements to reflectactual results, changes in assumptions or other changes affecting suchforward-looking statements.